Collegium Pharmaceutical Q3 Earnings Call Highlights
Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.
How this was made

The 30-second read
Why it matters
The mixed earnings results introduce both downside from pain‑portfolio weakness and upside from the share buyback and AZSTARYS growth outlook.
Market read
Earnings release offers actionable data on revenue trends, margin pressure, and capital allocation, influencing short‑term price dynamics.
What to watch
Potential upside from AZSTARYS growth and JORNAY PM contributions not fully reflected yet.
Background
Collegium Pharmaceutical provided its Q3 earnings call highlights, including product sales, gross‑to‑net metrics, guidance, cash flow, debt levels, and a planned share repurchase.
Ticker impact
Q3 earnings release with revenue, margin, guidance and share repurchase details provides fresh material for the stock.
likely pressure as market prices in weaker pain sales despite buyback announcement
Revenue decline in key products and higher gross-to-net deductions suggest margin pressure, while a $50M accelerated repurchase offers support.
Market effects
Pain‑management pharma sector may see scrutiny on generic competition and margin pressure.
U.S. specialty pharma stocks could experience modest volatility.
Limited to U.S. investors; no broader macro impact.
Counterpoint
Buyback could signal confidence; price may rally if investors focus on capital return rather than sales decline.
Key entities
- companyCollegium Pharmaceutical
Specialty pharma firm reporting Q3 results.
- executiveKaran Karnani
CEO providing commentary on product outlook.
- executiveColleen Tupper
CFO discussing financial metrics.


